Newron Pharmaceuticals SpA achieved revenue of €2.4 million in 2015, an increase of 53% from a year earlier as the result of the approval and successful launch in Europe of its lead product for Parkinson’s disease Xadago (safinamide).
Autolus Ltd, a spin-out from University College London (UCL) that is developing engineered T cell therapies for cancer, has raised £40 million in a Series B financing round bringing total commitments to date from private investors to £70 million.
A new oncology joint venture has been set up in the UK to exploit the gene editing capabilities of Horizon Discovery Group Plc and aptamer technology developed in the US and owned by Centauri Therapeutics Ltd, a UK anti-infectives company.
MorphoSys AG plans to increase spending on research and development this year as two of its proprietary antibody drugs approach clinical proof of concept, and two earlier compounds prepare for their first human trials.
A new France-based company has been launched to exploit peptide technology developed by scientists from the University of Strasbourg and the French Institute of Health and Medical Research (Inserm) in order develop drugs for oncology and immune disorders.
NeuroVive Pharmaceutical AB, a Swedish biotech specialising in mitochondria protection, is planning to raise SEK 94.4 million (€10.14 million) to finance completion of two Phase 2 studies for its kidney and brain injury compounds.
Sobi, whose full name is Swedish Orphan Biovitrum AB, reported a 24% increase in revenue to SEK 3.2 billion for 2015 and expects a revenue gain averaging 36% in 2016.
UCB SA, the Belgian specialty pharmaceutical company, reported a 16% increase in revenue to about €3.9 billion in 2015. If exchange-rate effects were eliminated, the revenue increase would come to 9.0%
Ablynx NV, a developer of antibody fragments originating in llamas, reported a 57% increase in revenue to €77.5 million for 2015 but its operating loss was 5% higher at €17 million
A project aimed at improving the properties of adeno-associated viral (AAV) vectors for use in gene therapy has been launched in the UK by Cobra Biologics Ltd, a contract research group, and the Center for Process Innovation, a UK government funded entity.